Phaseline

Companies › Shanghai Vitalgen BioPharma

Shanghai Vitalgen BioPharma: clinical trials, targets and expected readouts

3 active drug programs in 5 registered trials: 3 Phase 1, 1 Phase 2, 1 Phase 3; Metabolic and endocrine, Neurology, Ophthalmology; next expected readout Dec 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
VGR-R01
CYP4V2-coding gene delivered by AAV vector
CYP4V2Phase 3Bietti Crystalline DystrophyDec 2026
VGN-R09b
Gene therapy delivering AADC gene to putamen
AADCPhase 2Aromatic L-amino Acid Decarboxylase Deficiency; Parkinson's DiseaseSep 2030
VGM-R02b
rAAV9-mediated GCDH gene replacement therapy
GCDHPhase 1Glutaric Acidemia Type IAug 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06699108VGR-R01Phase 3Bietti Crystalline DystrophyOphthalmologyDec 2026
NCT06217861VGM-R02bPhase 1Glutaric Acidemia Type IMetabolic and endocrineAug 2027
NCT05694598VGR-R01Phase 1Bietti Crystalline DystrophyOphthalmologySep 2028
NCT06480461VGN-R09bPhase 1Parkinson's DiseaseNeurologySep 2030
NCT06432140VGN-R09bPhase 2Aromatic L-amino Acid Decarboxylase DeficiencyMetabolic and endocrineSep 2030

Targets

AADC (1) GCDH (1) CYP4V2 (1)

Companies with the same targets

NGGT (Suzhou) Biotechnology

Companies built like this

Amylyx Pharmaceuticals Innovent Biologics Technology Limited (Shanghai R&D Center) Beijing Suncadia Pharmaceuticals Rhythm Pharmaceuticals BioMarin Pharmaceutical

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.